Clinical Trials Browser

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male

NCT00621725 2014-07-15

Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours

Phase 1 Completed

36 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT00458731 2014-02-19

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

Phase 1 Completed

57 enrolled

LymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

NCT00243347 2013-10-17

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

Phase 1 Completed

19 enrolled 7 charts

Head & NeckThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT00937482 2013-03-08

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Phase 1 Terminated

18 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Melanoma, Rectal Neoplasms, Breast Neoplasms, Male

NCT00621361 2012-12-17

Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients

Phase 1 Completed

62 enrolled

Thoracic

Lung Neoplasms

NCT00748891 2011-07-01

DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)

Phase 1 Completed

35 enrolled

Tumor-Agnostic

Neoplasms

NCT00981721 2011-06-20

A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies

Phase 1 Completed

20 enrolled

Advanced Solid Malignancies

NCT00960349 2011-06-14

Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients

Phase 1 Completed

14 enrolled

Gastrointestinal

Stomach Neoplasms

NCT00539331 2011-06-01

Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients

Phase 1 Terminated

6 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00750425 2011-03-10

Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours

Phase 1 Completed

46 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT00502385 2011-01-21

Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML

Phase 1 Completed

54 enrolled

Other hematologic neoplasm

Leukemia

NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

Phase 1 Completed

40 enrolled

BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

NCT00503204 2009-11-25

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

Phase 1 Completed

20 enrolled

CNS

Brain Neoplasms, Glioblastoma, Neoplasms

NCT00502060 2009-05-14

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

Phase 1 Completed

65 enrolled

Advanced Tumor

NCT00503412 2009-01-19

Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors

Phase 1 Completed

6 enrolled

Tumor-Agnostic

Neoplasm Metastasis

Clinical Trials

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer

DREAMtherapy

AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies

AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients

DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)

A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies

Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients

Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients

Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours

Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors